Abstract
Purpose
Patients with vestibular schwannoma undergoing definitive radiotherapy commonly experience hearing loss due to tumor and treatment effects; however, there is limited data evaluating concurrent medication use and other clinicopathologic factors associated with hearing preservation during and after radiotherapy. We performed a retrospective cohort study reviewing consecutive patients from 2004 to 2019 treated with radiotherapy for vestibular schwannoma at our institution.
Methods
Ninety four patients with concurrent medications, baseline audiograms, and post-radiotherapy audiograms available were evaluable. We performed chi-squared analyses of the frequency of various clinicopathologic factors and t-tests evaluating the degree of hearing loss based on audiograms.
Results
At a median follow-up of 35.7 months (mean: 46.5 months), the baseline pure-tone average (PTA) of the ipsilateral ear worsened from 38.4 to 59.5 dB following completion of radiotherapy (difference: 21.1, 95% CI 17.8–24.4 dB, p < 0.001). 36 patients (38.3%) reported regular use of cyclooxygenase (COX) inhibitors (including acetaminophen and NSAIDs) during radiotherapy. The mean increase in PTA was significantly higher for patients taking COX inhibitors (25.8 dB vs 18.1 dB, p = 0.024) in the ipsilateral ear but not for the contralateral side. COX inhibitor use remained independently associated with worse PTA in the multivariate analysis.
Conclusion
COX inhibitor use during definitive radiotherapy is associated with worse hearing loss in the affected ear but not for the contralateral side. This suggests the ototoxic effects of COX inhibitors may influence the effects of radiotherapy. These results could have clinical implications and warrant further investigation.
Similar content being viewed by others
Data availability
The data that support the findings of this study are available from the corresponding author, Chi Zhang, upon reasonable request.
References
Marinelli JP, Lohse CM, Carlson ML (2018) Incidence of vestibular schwannoma over the past half-century: a population-based study of Olmsted county Minnesota. Otolaryngol Head Neck Surg 159(4):717–723. https://doi.org/10.1177/0194599818770629
Chen Z, Prasad SC, Di Lella F et al (2014) The behavior of residual tumors and facial nerve outcomes after incomplete excision of vestibular schwannomas. J Neurosurg 120(6):1278–1287. https://doi.org/10.3171/2014.2.jns131497
Stangerup SE, Caye-Thomasen P, Tos M, Thomsen J (2006) The natural history of vestibular schwannoma. Otol Neurotol 27(4):547–552. https://doi.org/10.1097/01.mao.0000217356.73463.e7
Gormley WB, Sekhar LN, Wright DC, Kamerer D, Schessel D (1997) Acoustic neuromas: results of current surgical management. Neurosurgery. 41(1):50–60. https://doi.org/10.1097/00006123-199707000-00012
Régis J, Pellet W, Delsanti C, Dufour H, Roche PH, Thomassin JM, Zanaret M, Peragut JC (2002) Functional outcome after gamma knife surgery or microsurgery for vestibular schwannomas. J Neurosurg 97(5):1091–1100. https://doi.org/10.3171/jns.2002.97.5.1091
Carlson ML, Tveiten OV, Driscoll CL, Goplen FK, Neff BA, Pollock BE, Tombers NM, Castner ML, Finnkirk MK, Myrseth E, Pedersen PH, Lund-Johansen M, Link MJ (2015) Long-term quality of life in patients with vestibular schwannoma: an international multicenter cross-sectional study comparing microsurgery, stereotactic radiosurgery, observation, and nontumor controls. J Neurosurg 122(4):833–842. https://doi.org/10.3171/2014.11.JNS14594
Carlson ML, Vivas EX, McCracken DJ et al (2018) Congress of neurological surgeons systematic review and evidence-based guidelines on hearing preservation outcomes in patients with sporadic vestibular schwannomas. Neurosurgery 82(2):E35–E39. https://doi.org/10.1093/neuros/nyx511
Combs SE, Engelhard C, Kopp C, Wiedenmann N, Schramm O, Prokic V, Debus J, Molls M, Grosu AL (2015) Long-term outcome after highly advanced single-dose or fractionated radiotherapy in patients with vestibular schwannomas - pooled results from 3 large German centers. Radiother Oncol 114(3):378–383. https://doi.org/10.1016/j.radonc.2015.01.011
Coughlin AR, Willman TJ, Gubbels SP (2018) Systematic review of hearing preservation after radiotherapy for vestibular schwannoma. Otol Neurotol 39(3):273–283. https://doi.org/10.1097/mao.0000000000001672
Persson O, Bartek J, Shalom NB, Wangerid T, Jakola AS, Förander P (2017) Stereotactic radiosurgery vs. fractionated radiotherapy for tumor control in vestibular schwannoma patients: a systematic review. Acta Neurochir 159(6):1013–1021. https://doi.org/10.1007/s00701-017-3164-6
Meijer OW, Vandertop WP, Baayen JC, Slotman BJ (2003) Single-fraction vs. fractionated linac-based stereotactic radiosurgery for vestibular schwannoma: a single-institution study. Int J Radiat Oncol Biol Phys 56(5):1390–1396. https://doi.org/10.1016/s0360-3016(03)00444-9
Massager N, Nissim O, Delbrouck C et al (2007) Irradiation of cochlear structures during vestibular schwannoma radiosurgery and associated hearing outcome. J Neurosurg 107(4):733–739. https://doi.org/10.3171/jns-07/10/0733
Paek SH, Chung HT, Jeong SS et al (2005) Hearing preservation after gamma knife stereotactic radiosurgery of vestibular schwannoma. Cancer 104(3):580–590. https://doi.org/10.1002/cncr.21190
Patel KS, Ng E, Kaur T et al (2019) Increased cochlear radiation dose predicts delayed hearing loss following both stereotactic radiosurgery and fractionated stereotactic radiotherapy for vestibular schwannoma. J Neurooncol 145(2):329–337. https://doi.org/10.1007/s11060-019-03299-5
Rasmussen R, Claesson M, Stangerup SE et al (2012) Fractionated stereotactic radiotherapy of vestibular schwannomas accelerates hearing loss. Int J Radiat Oncol Biol Phys 83(5):e607–e611. https://doi.org/10.1016/j.ijrobp.2012.01.078
Thomas C, Di Maio S, Ma R et al (2007) Hearing preservation following fractionated stereotactic radiotherapy for vestibular schwannomas: prognostic implications of cochlear dose. J Neurosurg 107(5):917–926. https://doi.org/10.3171/jns-07/11/0917
Curhan SG, Eavey R, Shargorodsky J, Curhan GC (2010) Analgesic use and the risk of hearing loss in men. Am J Med 123(3):231–237. https://doi.org/10.1016/j.amjmed.2009.08.006
Curhan SG, Shargorodsky J, Eavey R, Curhan GC (2012) Analgesic use and the risk of hearing loss in women. Am J Epidemiol 176(6):544–554. https://doi.org/10.1093/aje/kws146
Honoré HB, Bentzen SM, Møller K, Grau C (2002) Sensori-neural hearing loss after radiotherapy for nasopharyngeal carcinoma: individualized risk estimation. Radiother Oncol 65(1):9–16. https://doi.org/10.1016/s0167-8140(02)00173-1
Gardner G, Robertson JH (1988) Hearing preservation in unilateral acoustic neuroma surgery. Ann Otol Rhinol Laryngol 97(1):55–66. https://doi.org/10.1177/000348948809700110
Lumley T, Diehr P, Emerson S, Chen L (2002) The importance of the normality assumption in large public health data sets. Annu Rev Public Health 23:151–169. https://doi.org/10.1146/annurev.publhealth.23.100901.140546
Rizk HG, Lee JA, Liu YF, Endriukaitis L, Isaac JL, Bullington WM (2020) Drug-induced ototoxicity: a comprehensive review and reference guide. Pharmacotherapy 40(12):1265–1275. https://doi.org/10.1002/phar.2478
Jereczek-Fossa BA, Zarowski A, Milani F, Orecchia R (2003) Radiotherapy-induced ear toxicity. Cancer Treat Rev 29(5):417–430. https://doi.org/10.1016/s0305-7372(03)00066-5
Bhandare N, Antonelli PJ, Morris CG, Malayapa RS, Mendenhall WM (2007) Ototoxicity after radiotherapy for head and neck tumors. Int J Radiat Oncol Biol Phys 67(2):469–479. https://doi.org/10.1016/j.ijrobp.2006.09.017
Formanek M, Czerny C, Gstoettner W, Kornfehl J (1998) Cochlear implantation as a successful rehabilitation for radiation-induced deafness. Eur Arch Otorhinolaryngol 255(4):175–178. https://doi.org/10.1007/s004050050038
Soussain C, Ricard D, Fike J, Mazeron JJ, Psimaras D, Delattre JY (2009) CNS complications of radiotherapy and chemotherapy. The Lancet 374(9701):1639–1651. https://doi.org/10.1016/S0140-6736(09)61299-X
Venkatesulu BP, Mahadevan LS, Aliru ML, Yang X, Bodd MH, Singh PK, Yusuf SW, Abe JI, Krishnan S (2018) Radiation-induced endothelial vascular injury: a review of possible mechanisms. JACC 3(4):563–572. https://doi.org/10.1016/j.jacbts.2018.01.014
Sugihara T, Hattori Y, Yamamoto Y, Qi F, Ichikawa R, Sato A, Liu MY, Abe K, Kanno M (1999) Preferential impairment of nitric oxide-mediated endothelium-dependent relaxation in human cervical arteries after irradiation. Circulation 100(6):635–641. https://doi.org/10.1161/01.cir.100.6.635
Carlson ML, Jacob JT, Pollock BE et al (2013) Long-term hearing outcomes following stereotactic radiosurgery for vestibular schwannoma: patterns of hearing loss and variables influencing audiometric decline. J Neurosurg 118(3):579–587. https://doi.org/10.3171/2012.9.jns12919
Mousavi SH, Niranjan A, Akpinar B et al (2016) Hearing subclassification may predict long-term auditory outcomes after radiosurgery for vestibular schwannoma patients with good hearing. J Neurosurg 125(4):845–852. https://doi.org/10.3171/2015.8.jns151624
Bojrab DI, Fritz CG, Lin KF, Schutt CA, Hong RS, Babu SC, Chen PY, Maitz A, Bojrab DI (2021) A protective cap: fundal fluid cap facilitates a reduction in inner ear radiation dose in the radiosurgical treatment of vestibular schwannoma. Otol Neurotol 42(2):294–299. https://doi.org/10.1097/MAO.0000000000002856
Bhandare N, Jackson A, Eisbruch A et al (2010) Radiation therapy and hearing loss. Int J Radiat Oncol Biol Phys 76(3 Suppl):S50–S57. https://doi.org/10.1016/j.ijrobp.2009.04.096
Lin BM, Curhan SG, Wang M, Eavey R, Stankovic KM, Curhan GC (2017) Duration of analgesic use and risk of hearing loss in women. Am J Epidemiol 185(1):40–47. https://doi.org/10.1093/aje/kww154
Jung TT, Rhee CK, Lee CS, Park YS, Choi DC (1993) Ototoxicity of salicylate, nonsteroidal antiinflammatory drugs, and quinine. Otolaryngol Clin North Am 26(5):791–810. https://doi.org/10.1016/S0030-6665(20)30767-2
Stypulkowski PH (1990) Mechanisms of salicylate ototoxicity. Hear Res 46(1–2):113–145. https://doi.org/10.1016/0378-5955(90)90144-e
Kalinec GM, Thein P, Parsa A et al (2014) Acetaminophen and NAPQI are toxic to auditory cells via oxidative and endoplasmic reticulum stress-dependent pathways. Hear Res 313:26–37. https://doi.org/10.1016/j.heares.2014.04.007
Funding
This work was supported by the Medical Student Summer Research Program author Benjamin G Huerter participated in through the University of Nebraska Medical Center. No other funds, grants, or support were received during the preparation of this manuscript.
Author information
Authors and Affiliations
Contributions
All authors excluding C. Zheng contributed to the chart review and manuscript writing. BGH, KCJ, and C. Zhang contributed to concept development. All authors excluding BT contributed to data analysis. All authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Conflict of interest
The authors have no relevant financial or non-financial interests to disclose.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Huerter, B.G., Johnson, K.C., Coutu, B.G. et al. COX inhibitor use during definitive radiotherapy is associated with worse hearing preservation in patients with vestibular schwannoma. J Neurooncol 165, 139–148 (2023). https://doi.org/10.1007/s11060-023-04462-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11060-023-04462-9